Compare RIVN & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIVN | HOLX |
|---|---|---|
| Founded | 2009 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical Electronics |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 16.9B |
| IPO Year | 2021 | 1995 |
| Metric | RIVN | HOLX |
|---|---|---|
| Price | $15.44 | $76.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 13 |
| Target Price | $17.74 | ★ $77.89 |
| AVG Volume (30 Days) | ★ 24.4M | 8.6M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.54 | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $5,387,000,000.00 | $4,100,500,000.00 |
| Revenue This Year | $32.97 | $4.74 |
| Revenue Next Year | $64.29 | $5.03 |
| P/E Ratio | ★ N/A | $96.23 |
| Revenue Growth | ★ 8.39 | 1.74 |
| 52 Week Low | $10.85 | $51.90 |
| 52 Week High | $22.69 | $76.07 |
| Indicator | RIVN | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 69.09 |
| Support Level | $14.20 | $75.10 |
| Resistance Level | $16.17 | N/A |
| Average True Range (ATR) | 0.75 | 0.19 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 52.41 | 95.19 |
Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company plans to begin selling a midsize SUV in 2026. Total deliveries were over 42,000 in 2025. Rivian is also developing autonomous driving software to be used in its vehicles.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.